Digital PCR Outperforms Standard RT-qPCR in Detecting Residual BCR::ABL1 in CML Patients, Enabling Better TKI Discontinuation Decisions
核心洞察
Digital PCR demonstrated 97% sensitivity at the MR5.0 level, reliably detecting one BCR::ABL1 (搜索) transcript in a background of at least 100,000 regular copies.
The technique detected and quantified BCR::ABL1 (搜索) in 68% of samples that fell below the limit of detection of standard RT-qPCR.
Digital PCR can identify transcript types (e13a2 vs. e14a2), a known risk factor for molecular relapse after TKI discontinuation.
A nationwide prospective multicenter study from the Netherlands has demonstrated that digital PCR (dPCR) for BCR::ABL1 (搜索) achieves superior sensitivity and accuracy compared to standard RT-qPCR in monitoring chronic myeloid leukemia (搜索) (CML) patients in deep molecular remission, potentially transforming clinical decision-making around tyrosine kinase inhibitor (TKI) discontinuation.
Lead investigator Peter E. Westerweel, MD, PhD, of the Department of Internal Medicine at Albert Schweitzer Hospital in Dordrecht, The Netherlands, and colleagues collected 168 samples from 136 CML patients across 31 medical centers between July 2020 and May 2023. All patients were being considered for a TKI discontinuation attempt.
Superior Sensitivity at Clinically Relevant Thresholds
The study found that digital PCR for BCR::ABL1 (搜索) reached sufficiently high sensitivity in 97% of samples from patients in deep molecular remission. The target sensitivity was set at MR5.0, which requires reliable detection of one transcript in a background of at least 100,000 regular copies. This threshold is clinically relevant because it represents the prediction cutoff in the context of treatment-free remission (TFR).
"BCR::ABL1 (搜索) digital PCR was found to accurately quantify BCR::ABL1 around the level of 0.0023% on the International Scale, which is the clinically relevant prediction cutoff in the context of treatment-free remission," Dr. Westerweel stated.
Critically, digital PCR was able to detect and quantify the BCR::ABL construct in 68% of samples that fell below the limit of detection of current standard RT-qPCR. This represents a substantial improvement in minimal residual disease monitoring capability.
Transcript Type Identification Adds Prognostic Value
An additional finding with direct clinical relevance emerged from the fluorescence patterns observed in the digital PCR assay. Researchers noted differences in fluorescence levels of droplets between patients, attributable to the transcript type carried by individual patients — either e13a2 or e14a2.
"We validated that the assay can be used to identify the transcript type in patients with detectable disease," Dr. Westerweel explained. "This additional discovery is very relevant as we have previously shown that the transcript type is a risk factor for molecular relapse after drug discontinuation. Often, the transcript type is not known for patients and cannot be established using standard techniques once patients are in deep remission."
Clinical Implications and Feasibility
The digital PCR assay used in this study is an FDA-approved commercially available product, which makes general clinical use feasible. This technology may improve the management of CML by enabling more precise monitoring of minimal residual disease and better risk assessment for patients considering treatment-free remission.
With targeted therapy using TKIs, patients with CML may achieve deep molecular responses. Those who reach this depth of remission can have a normal life expectancy and may qualify for a TKI discontinuation attempt. The ability to more accurately determine which patients are suitable candidates for discontinuation has significant implications for quality of life and healthcare resource utilization.
"Digital PCR for BCR::ABL is a valuable and reliable tool to aid clinical decision making in CML," Dr. Westerweel concluded.